Medical Condition News

RSS

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

La Jolla researchers create first cellular movies showing destruction underlying type 1 diabetes

A war is being waged in the pancreases of millions of people throughout the world. The siege leads to the development of type 1 diabetes and has been a battlefield largely hidden from view-- until now.

3 Dec 2011

CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension

Shire plc, the global specialty biopharmaceutical company, announces that it has reached an agreement with the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration to conduct additional clinical trials to confirm the clinical benefit of ProAmatine (midodrine HCl), a medicine approved in 1996 under Subpart H for the treatment of symptomatic orthostatic hypotension (SOH).

3 Dec 2011

Four clinical centers to provide NovoTTF device treatment for recurrent GBM

Novocure, a commercial stage private oncology company, has announced that prominent neuro-oncologists at four clinical centers in the U.S. will be the first to provide access to its Tumor Treating Fields (TTFields) device, NovoTTF-100A System, for the treatment of recurrent glioblastoma multiforme. GBM is a deadly brain tumor affecting approximately 10,000 Americans each year.

3 Dec 2011

Mainz gastroenterologist awarded ERC Advanced Grant

The European Research Council (ERC) has earmarked about €2.5 mio. to fund the research being conducted by gastroenterologist and biochemist Professor Dr. Dr. Detlef Schuppan at Mainz University Medical Center.

3 Dec 2011

NASA-developed technology for treatment of hardened arteries in the heart

NASA has signed a patent license agreement that will allow a California company use of NASA-developed technology that could be used to treat hardened arteries in the heart.

3 Dec 2011

American Plasma Users Coalition awarded $40,000 advocacy grant from CSL Behring

CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders.

3 Dec 2011

World Cell Race pulls 70 entries for title of world's fastest cell

A "team" of fast-moving, bone marrow stem cells from a research laboratory in Singapore has run away with the first World Cell Race, finishing first with a cellular speed record of 5.2 microns per minute (or 0.000204 inches per minute) in results announced today at the 51st Annual Meeting of the American Society for Cell Biology (ASCB).

3 Dec 2011

Study identifies sulfomucins as potential targets for therapies to treat chronic intestinal inflammatory disorders

In a paper published in the December 2011 issue of Experimental Biology and Medicine, a team of scientists at the University of Illinois, Urbana-Champaign led by Rex Gaskins, PhD have demonstrated that both microbial and host inflammatory factors modulate sulfomucin production in a human cell line, LS174T, that models intestinal goblet cells.

3 Dec 2011

Better medical care for kidney failure in Germany

In complex cases of kidney failure, medical care in Germany evidently operates better than in the US. Scientists at Charité - Universitätsmedizin Berlin were able to show that German patients who have an increased risk of rejection reactions due to prior immunization have better survival rates than people with diseases of similar severity in the US.

3 Dec 2011

New technique allows production of medically useful amounts of endoderm cells from human PSCs

Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known as the 'valley of death'.

3 Dec 2011

Genitourinary injuries now on list of payable losses under TSGLI program

Servicemembers who suffer severe injuries to the genitourinary organs will now be eligible for Servicemembers' Group Life Insurance Traumatic Injury Protection, or TSGLI.

3 Dec 2011

Implantable replacement cartilages hold promise for damaged knees, shoulders, ears and noses

A lab discovery is a step toward implantable replacement cartilage, holding promise for knees, shoulders, ears and noses damaged by osteoarthritis, sports injuries and accidents.

3 Dec 2011

Study directly quantifies magnitude of asthma among WTC responders

The American Journal of Industrial Medicine recently published a study showing that World Trade Center (WTC) responders suffer from asthma at more than twice the rate of the general U.S. population as a result of their exposure to the toxic dust from the collapse of the WTC towers in 2001. Preliminary study results were previously presented in CHEST in 2009.

3 Dec 2011

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

Mayo Clinic researchers have identified critical steps leading to myelin destruction in neuromyelitis optica (NMO), a debilitating neurological disease that is commonly misdiagnosed as multiple sclerosis (MS). The findings could lead to better care for the thousands of patients around the world with NMO. The paper was published in the journal, Proceedings of the National Academy of Sciences, USA.

3 Dec 2011

FDA approves Mylan's Tranexamic Acid Injection ANDA

Mylan Inc. today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials.

3 Dec 2011

Dye derived from Canary Island lichens may help treat Alzheimer's disease

A red dye derived from lichens that has been used for centuries to color fabrics and food appears to reduce the abundance of small toxic protein aggregates in Alzheimer's disease. The dye, a compound called orcein, and a related substance, called O4, bind preferentially to small amyloid aggregates that are considered to be toxic and cause neuronal dysfunction and memory impairment in Alzheimer's disease.

3 Dec 2011

Promising new agent against sarcomas affecting children

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.

3 Dec 2011

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

Oncolytics Biotech Inc. today announced that interim data from a Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with gemcitabine (Gemzar) in patients with advanced pancreatic cancer (REO 017) indicated that the clinical study had successfully reached its primary endpoint, and that the drug combination is active.

3 Dec 2011

NIAAA awards Rutgers $10M grant to explore genetic links to alcoholism

Rutgers University Cell and DNA Repository (RUCDR) has received a $10 million grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) to provide DNA extraction, basic genetic testing, and repository services for more than 46,000 saliva samples, in support of national research efforts to determine the genetic and environmental factors that lead to alcoholism.

3 Dec 2011

Medical Condition News

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla researchers create first cellular movies showing destruction underlying type 1 diabetes

CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension

Four clinical centers to provide NovoTTF device treatment for recurrent GBM

Mainz gastroenterologist awarded ERC Advanced Grant

NASA-developed technology for treatment of hardened arteries in the heart

American Plasma Users Coalition awarded $40,000 advocacy grant from CSL Behring

World Cell Race pulls 70 entries for title of world's fastest cell

Study identifies sulfomucins as potential targets for therapies to treat chronic intestinal inflammatory disorders

Better medical care for kidney failure in Germany

New technique allows production of medically useful amounts of endoderm cells from human PSCs

Genitourinary injuries now on list of payable losses under TSGLI program

Implantable replacement cartilages hold promise for damaged knees, shoulders, ears and noses

Study directly quantifies magnitude of asthma among WTC responders

Researchers identify critical steps leading to myelin destruction in neuromyelitis optica

FDA approves Mylan's Tranexamic Acid Injection ANDA

Dye derived from Canary Island lichens may help treat Alzheimer's disease

Promising new agent against sarcomas affecting children

Oncolytics REOLYSIN-Gemzar combination Phase 2 pancreatic cancer clinical trial meets primary endpoint

NIAAA awards Rutgers $10M grant to explore genetic links to alcoholism

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News